Next Article in Journal
Treatment with Human Amniotic Suspension Allograft Improves Tendon Healing in a Rat Model of Collagenase-Induced Tendinopathy
Previous Article in Journal
Thioalbamide, A Thioamidated Peptide from Amycolatopsis alba, Affects Tumor Growth and Stemness by Inducing Metabolic Dysfunction and Oxidative Stress
Open AccessArticle

Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis

1
Department of Laboratory Medicine, Translational Cancer Research, Lund University, Medicon Village, 223 63 Lund, Sweden
2
NeuroVive Pharmaceutical AB, 223 63 Lund, Sweden
3
Engitix Ltd., London NW3 2PF, UK
4
Regenerative Medicine & Fibrosis Group, Institute for Liver & Digestive Health, University College London, Royal Free Hospital, London NW3 2PF, UK
5
Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA
6
Isomerase Therapeutics Ltd., Cambridge CB10 1XL, UK
7
Mitochondrial Medicine, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, 221 84 Lund, Sweden
*
Authors to whom correspondence should be addressed.
Cells 2019, 8(11), 1409; https://doi.org/10.3390/cells8111409
Received: 11 October 2019 / Revised: 31 October 2019 / Accepted: 6 November 2019 / Published: 8 November 2019
Hepatic fibrosis can result as a pathological response to nonalcoholic steatohepatitis (NASH). Cirrhosis, the late stage of fibrosis, has been linked to poor survival and an increased risk of developing hepatocellular carcinoma, with limited treatment options available. Therefore, there is an unmet need for novel effective antifibrotic compounds. Cyclophilins are peptidyl-prolyl cis-trans isomerases that facilitate protein folding and conformational changes affecting the function of the targeted proteins. Due to their activity, cyclophilins have been presented as key factors in several stages of the fibrotic process. In this study, we investigated the antifibrotic effects of NV556, a novel potent sanglifehrin-based cyclophilin inhibitor, in vitro and in vivo. NV556 potential antifibrotic effect was evaluated in two well-established animal models of NASH, STAM, and methionine-choline-deficient (MCD) mice, as well as in an in vitro 3D human liver ECM culture of LX2 cells, a human hepatic stellate cell line. We demonstrate that NV556 decreased liver fibrosis in both STAM and MCD in vivo models and decreased collagen production in TGFβ1-activated hepatic stellate cells in vitro. Taken together, these results present NV556 as a potential candidate for the treatment of liver fibrosis. View Full-Text
Keywords: cyclophilin; liver fibrosis; NV556; methionine-choline-deficient (MCD) diet; nonalcoholic steatohepatitis; STAM; hepatic stellate cells (HSC); 3D in vitro model; decellularized human liver cyclophilin; liver fibrosis; NV556; methionine-choline-deficient (MCD) diet; nonalcoholic steatohepatitis; STAM; hepatic stellate cells (HSC); 3D in vitro model; decellularized human liver
Show Figures

Figure 1

MDPI and ACS Style

Simón Serrano, S.; Grönberg, A.; Longato, L.; Rombouts, K.; Kuo, J.; Gregory, M.; Moss, S.; Elmér, E.; Mazza, G.; Gallay, P.; Pinzani, M.; Hansson, M.J.; Massoumi, R. Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis. Cells 2019, 8, 1409.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop